You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 291 No. 9, March 3, 2004 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Pulmonary Diseases
 •Chronic Obstructive Pulmonary Disease
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Management of Chronic Obstructive Pulmonary Disease—Reply

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: In reponse to Dr Ewart, Butler et al1 reported an efficacy of 57% in preventing pneumococcal sepsis or meningitis by serotypes included in the pneumococcal vaccine, and of 65% in patients with COPD. Robinson et al2 reported that 28.6% of patients with invasive pneumococcal disease were at least 65 years of age, which suggests that the beneficial effects may be even more pronounced in the elderly population. Importantly, 86% of cases in this age group were due to serotypes included in the 23-valent polysaccharide pneumococcal vaccine. Consistent with these data, in a recent Cochrane review that Ewart cites, the authors concluded that " . . . the [pneumococcal] vaccines are effective in reducing the incidence of the more specific outcome, invasive pneumococcal disease, among adults and the immunocompetent elderly (55 years and above)."3 As pneumococcal vaccines are generally safe, we recommend vaccinating patients aged 65 years or older . . . [Full Text of this Article]

Don D. Sin, MD, MPH
don.sin@ualberta.ca

S. F. Paul Man, MD
Division of Pulmonary Medicine

Finlay A. McAlister, MD, MSc
Department of General Medicine
University of Alberta
Edmonton

Nick R. Anthonisen, MD, PhD
Department of Medicine
University of Manitoba
Winnipeg



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Management of Chronic Obstructive Pulmonary Disease
Robert M. Ewart
JAMA. 2004;291(9):1066.
EXTRACT | FULL TEXT  

Management of Chronic Obstructive Pulmonary Disease
R. Graham Barr
JAMA. 2004;291(9):1066-1067.
EXTRACT | FULL TEXT  

Contemporary Management of Chronic Obstructive Pulmonary Disease: Scientific Review
Don D. Sin, Finlay A. McAlister, S. F. Paul Man, and Nick R. Anthonisen
JAMA. 2003;290(17):2301-2312.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2004 American Medical Association. All Rights Reserved.